SER · Insider Trading
Serina Therapeutics, Inc.
Every open-market purchase and sale reported by SER officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-23 | Farrell Simon | Director | A | +30,500 deriv. | — |
| 2026-07-09 | Stephen K. Brannan | Director | Buy | +1,000 | +$2.03K |
| 2026-06-22 | Stephen K. Brannan | Director | A | +15,250 deriv. | — |
| 2026-06-22 | Jay Venkatesan | Director | MIXED | +224,741 | +$505.39K |
| 2026-06-22 | Gregory Bailey | Director | C | +8,437,472 | +$18.98M |
| 2026-06-22 | Karen J Wilson | Director | A | — | — |
| 2026-06-22 | Richard Peter Marshall | Director | A | +15,250 deriv. | — |
| 2026-06-15 | Karen J Wilson | Director | Buy | +10,100 | +$17.75K |
| 2026-05-27 | Steven A Ledger | Chief Executive Officer | A | +10,100 | +$19.49K |
| 2026-05-26 | Srini Tenjarla | SVP, CMC & Formulation | A | +85,558 deriv. | — |
| 2026-05-26 | Steven A Ledger | Chief Executive Officer | A | +380,825 deriv. | — |
| 2026-05-26 | Karen J Wilson | Director | Buy | +20,000 | +$37.00K |
| 2026-05-26 | Randall Moreadith | Chief Scientific Officer | A | +85,558 deriv. | — |
| 2026-05-26 | Gregory S Curhan | Chief Financial Officer | A | +123,019 deriv. | — |
| 2026-05-22 | Richard Peter Marshall | Director | Buy | +12,183 | +$20.10K |
| 2026-04-21 | Gregory Bailey | Director | A | +59,667 | +$115.75K |
| 2026-04-21 | Jay Venkatesan | Director | A | +7,553 | +$14.65K |
| 2026-03-24 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$18.18K |
| 2026-03-20 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$95.16K |
| 2026-02-17 | Srini Tenjarla | SVP, CMC & Formulation | A | +69,000 deriv. | — |
| 2026-02-17 | Steven A Ledger | Chief Executive Officer | A | +230,100 deriv. | — |
| 2026-02-17 | Simba Gill | Director | A | +92,000 deriv. | — |
| 2026-02-17 | Randall Moreadith | Chief Scientific Officer | A | +69,000 deriv. | — |
| 2026-02-03 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$19.29K |
| 2026-01-29 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$22.80K |
| 2026-01-23 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$7.22K |
| 2026-01-21 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$11.90K |
| 2026-01-14 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$15.86K |
| 2026-01-09 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$34.17K |
| 2025-12-29 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$10.41K |
| 2025-12-23 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$14.83K |
| 2025-12-17 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$9.37K |
| 2025-12-16 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$5.44K |
| 2025-12-12 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$11.31K |
| 2025-12-11 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$4.07K |
| 2025-12-04 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$23.09K |
| 2025-11-26 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$22.91K |
| 2025-11-25 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$2.07K |
| 2025-11-19 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$24.01K |
| 2025-11-12 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$26.26K |
| 2025-11-10 | Karen J Wilson | Director | A | +10,000 deriv. | — |
| 2025-11-10 | Jay Venkatesan | Director | A | +10,000 deriv. | — |
| 2025-11-10 | Stephen K. Brannan | Director | A | +10,000 deriv. | — |
| 2025-11-10 | Gregory Bailey | Director | A | +10,000 deriv. | — |
| 2025-11-10 | Richard Peter Marshall | Director | A | +10,000 deriv. | — |
| 2025-11-06 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$14.20K |
| 2025-11-05 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$13.45K |
| 2025-10-29 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$27.21K |
| 2025-10-28 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$4.86K |
| 2025-10-21 | Randall Moreadith | Chief Scientific Officer | MIXED | — | −$31.90K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Juvenescence Ltd | 10%+ Owner | 2,767,188 | $3.78M |
| Gregory Bailey | Director | 1,897,445 | $2.59M |
| Jay Venkatesan | Director | 232,294 | $317.08K |
| Karen J Wilson | Director | 30,100 | $41.09K |
| Richard Peter Marshall | Director | 12,183 | $16.63K |
| Steven A Ledger | Chief Executive Officer | 10,100 | $13.79K |
| Stephen K. Brannan | Director | 1,000 | $1.36K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SER quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.